siRNA therapy reduces triglycerides in patients along with rare disorder

.RESEARCH STUDY HIGHLIGHT.19 September 2024.

Plozasiran lowered triglyceride levels through 80% and also decreased the danger of pancreatitis in patients with relentless chylomicronemia, with or even without a hereditary prognosis.